04 June 2026
04 June 2026
Insulet has begun shipping Omnipod 5 pods with the new algorithm to US retailers ahead of a broader software update.
The study is said to be the first to demonstrate efficacy for FcRn inhibition in SLE.
The partnership brings together CytomX’s biologic masking technology and Regeneron’s expertise in bispecific antibodies.
The study marks the first-in-human trial of MOON101 and plans to enrol up to 40 participants at various clinical sites across the US.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
